Entry Point Capital, LLC Vera Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
Shares
2 transactions
Others Institutions Holding VERA
# of Institutions
193Shares Held
63.9MCall Options Held
68.1KPut Options Held
88.6K-
Avoro Capital Advisors LLC New York, NY5.61MShares$152 Million3.46% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.38MShares$119 Million0.02% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$90.4 Million0.0% of portfolio
-
Abingworth LLP London, X02.96MShares$80.2 Million19.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.95MShares$79.9 Million0.0% of portfolio
About Vera Therapeutics, Inc.
- Ticker VERA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,042,300
- Market Cap $732M
- Description
- Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...